ATHE ALTERITY THERAPEUTICS LTD IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1131343 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2018-06-30 (FY2018), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY2025*2025-06-30 | FY2024*2024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 14.40M | 18.64M | 13.20M | 14.75M | 12.28M |
| SG&A expense | 5.48M | 4.76M | 5.06M | 5.51M | 6.94M |
| Interest expense | 6,188 | 7,217 | 4,565 | 2,285 | 1,299 |
| Pretax income | -12.08M | -19.08M | -13.70M | -12.78M | -15.31M |
| Income tax | 68,055 | 46,088 | 104,459 | 70,008 | — |
| Net income | -12.15M | -19.12M | 13.81M | 12.85M | 15.31M |
| EPS (basic) | -0.19 | -0.52 | -0.57 | -0.53 | -0.90 |
| EPS (diluted) | -0.19 | -0.52 | -0.57 | -0.53 | -0.90 |
| Weighted avg. shares (diluted) | 6.40B | 3.65B | 2.43B | 2.41B | 1.70B |
| Balance sheet | |||||
| Cash & equivalents | 33.16M | 12.64M | 15.77M | 34.81M | 28.12M |
| Receivables | 3.94M | 4.04M | 8.67M | 4.73M | 4.28M |
| Current assets | 45.87M | 19.04M | 27.05M | 41.14M | 33.49M |
| PP&E, netmay include right-of-use assets (IFRS) | 3,848 | 32,154 | 61,776 | 102,551 | 31,313 |
| Total assets | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Current liabilities | 3.53M | 5.37M | 4.38M | 5.82M | 3.07M |
| Total liabilities | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Shareholders' equity | -225.89M | -214.16M | -195.13M | 35.47M | 30.47M |
| Shares outstanding | — | — | 2.44B | 2.41B | 2.08B |
| Cash flow statement | |||||
| Operating cash flow | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Capital expenditure | — | 5,722 | 7,311 | 89,147 | 10,472 |
| Free cash flow | — | -12.61M | -20.04M | -12.43M | -17.34M |
| Investing cash flow | -7.50M | -5,722 | -36,461 | -89,147 | -10,472 |
| Financing cash flow | 39.67M | 9.22M | 124,340 | 16.30M | 36.69M |
| Stock-based compensation | 979,920 | 881,950 | 966,571 | 1.51M | 1.95M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.